What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...

Many children born during Venezuela's crisis suffer from malnutrition. Father Jose Maria Gimeno has a mission - he wants to convert parents in Venezuela's slums to cheaper soy products instead of meat ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

From cabbage soup to the F-plan, quick fix diets promise everything from miracle weight loss to eternal youth – but do any of ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

FundCanna is redefining cannabis financing with flexible loans, fueling 61% average growth for operators, and solving ...

Dick's Drive-In is celebrating the chain's 71st anniversary with 19-cent hamburgers and cheeseburgers at all nine of its ...

A recent high school graduate and former Neuralink intern has joined meetings to review lines of code and other work history ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent studies highlight side effects such as heart muscle weakening and skin ...

By Dani Blum The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease.